//fpnotebook.com/
Serotype B Meningococcal Vaccine
Aka: Serotype B Meningococcal Vaccine, Meningococcal Serogroup B, Trumenba, MenB-FHbp, Bexsero, MenB-4C
- See Also
- Meningococcal Vaccine (Menactra, Menveo, MCV4)
- Menomune (MPSV4)
- Neisseria Meningitidis
- Bacterial Meningitis
- Indications (age 10 years old or older)
- Serotype B Meningococcal Meningitis exposure
- Asplenia
- Sickle Cell Disease
- Specific immune deficiency
- Mechanism
- Covers only Serotype B Meningococcus
- Accounts for one third of meningococcal cases
- Serotype B outbreaks are most common in infants and college students
- Contrast with Menactra, Menveo and Menomune which cover serotypes A, C, W and Y
- Indicated for all U.S. children as part of the Primary Series
- Preparations (FDA approved in 2014)
- Must use same preparation for both doses (not interchangeable)
- MenB-FHbp (Trumenba)
- Two dose regimen at least 6 months apart (0 and 6 months)
- Two dose regimen may be used for healthy patients ages 16-23 years AND
- Not at increased meningococcal disease
- Three dose series (0, 2 and 6 months)
- Indicated for Asplenia, complement deficiency, or complement inhibitor
- MenB-4C (Bexsero)
- Two dose series at least 1 month apart (0 and 1-6 months)
- Resources
- CDC Immunization Schedules (last accessed 10/28/2020)
- https://www.cdc.gov/vaccines/schedules/
- References
- Jacobson (2017) Vaccine Update,Mayo Clinic Reviews, Rochester, MN
- (2015) Presc Lett 22(10): 59
- Ackerman (2015) Am Fam Physician 92(6): 460-8 [PubMed]
- Cohn (2013) MMWR Recomm Rep 62(RR-2):1-28 [PubMed]